Literature DB >> 20154333

Novel myelin penta- and hexa-acetyl-galactosyl-ceramides: structural characterization and immunoreactivity in cerebrospinal fluid.

Maria Podbielska1, Somsankar Dasgupta, Steven B Levery, Wallace W Tourtellotte, Heidi Annuk, Anthony P Moran, Edward L Hogan.   

Abstract

Fast migrating cerebrosides (FMC) are derivatives of galactosylceramide (GalCer). The structures of the most hydrophobic FMC-5, FMC-6, and FMC-7 were determined by electrospray ionization linear ion-trap mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy complementing previous NMR spectroscopy and gas chromatography-mass spectrometry to be 3-O-acetyl-sphingosine-GalCer derivatives with galactose O-acetyl modifications. FMC-5 and FMC-6 are 3-O-acetyl-sphingosine-2,3,4,6-tetra-O-acetyl-GalCer with nonhydroxy and hydroxy-N-fatty-acids, while FMC-7 has an additional O-acetylation of the 2-hydroxy-fatty acid. The immuno-reactivity in human cerebrospinal fluid (CSF) to these acetylated glycolipids was examined in central nervous system (CNS) infectious disease, noninflammatory disorders, and multiple sclerosis (MS). Screening for lipid binding in MS and other neurological disease groups revealed that the greatest anti-hydrophobic FMC reactivity was observed in the inflammatory CNS diseases (meningitis, meningo-encephalitis, and subacute sclerosing panencephalitis). Some MS patients had increased reactivity with the hydrophobic FMCs and with glycoglycerophospholipid MfGL-II from Mycoplasma fermentans. The cross-reactivity of highly acetylated GalCer with microbial acyl-glycolipid raises the possibility that myelin-O-acetyl-cerebrosides, bacterial infection, and neurological disease are linked.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20154333      PMCID: PMC3035502          DOI: 10.1194/jlr.M001396

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  33 in total

1.  Structural elucidation of the O-antigenic polysaccharide from enterohemorrhagic (EHEC) Escherichia coli O48:H21.

Authors:  Leann L MacLean; Ann C Webb; Malcolm B Perry
Journal:  Carbohydr Res       Date:  2006-09-01       Impact factor: 2.104

2.  Isolation and structural analysis of phosphorylated oligosaccharides obtained from Escherichia coli J-5 lipopolysaccharide.

Authors:  S Müller-Loennies; O Holst; B Lindner; H Brade
Journal:  Eur J Biochem       Date:  1999-02

3.  Structural studies on the Shigella-like Escherichia coli O121 O-specific polysaccharide.

Authors:  H Parolis; L A Parolis; G Olivieri
Journal:  Carbohydr Res       Date:  1997-09-26       Impact factor: 2.104

4.  Stage-specific expression of fuco-neolacto- (Lewis X) and ganglio-series neutral glycosphingolipids during brain development: characterization of Lewis X and related glycosphingolipids in bovine, human and rat brain.

Authors:  S Dasgupta; E L Hogan; S S Spicer
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

5.  Complex O-acetylation in non-typeable Haemophilus influenzae lipopolysaccharide: evidence for a novel site of O-acetylation.

Authors:  Håkan H Yildirim; Jianjun Li; James C Richards; Derek W Hood; E Richard Moxon; Elke K H Schweda
Journal:  Carbohydr Res       Date:  2005-09-30       Impact factor: 2.104

6.  Structural determination of the O-antigenic polysaccharide from the Shiga toxin-producing Escherichia coli O171.

Authors:  Tara Ali; Andrej Weintraub; Göran Widmalm
Journal:  Carbohydr Res       Date:  2006-05-15       Impact factor: 2.104

7.  Neutral monoglycosylceramides in rat brain: occurrence, molecular expression and developmental variation.

Authors:  S Dasgupta; M B Everhart; N R Bhat; E L Hogan
Journal:  Dev Neurosci       Date:  1997       Impact factor: 2.984

8.  Electrospray ionization tandem mass spectrometric analysis of sulfatide. Determination of fragmentation patterns and characterization of molecular species expressed in brain and in pancreatic islets.

Authors:  F F Hsu; A Bohrer; J Turk
Journal:  Biochim Biophys Acta       Date:  1998-06-15

Review 9.  Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept.

Authors:  M B A Oldstone
Journal:  Curr Top Microbiol Immunol       Date:  2005       Impact factor: 4.291

Review 10.  Molecular mimicry and immune-mediated diseases.

Authors:  M B Oldstone
Journal:  FASEB J       Date:  1998-10       Impact factor: 5.191

View more
  7 in total

Review 1.  Invariant natural killer T cells and their ligands: focus on multiple sclerosis.

Authors:  Joan O'Keeffe; Maria Podbielska; Edward L Hogan
Journal:  Immunology       Date:  2015-06-25       Impact factor: 7.397

2.  The structural and functional role of myelin fast-migrating cerebrosides: pathological importance in multiple sclerosis.

Authors:  Maria Podbielska; Steven B Levery; Edward L Hogan
Journal:  Clin Lipidol       Date:  2011-04

Review 3.  Sphingolipid Players in Multiple Sclerosis: Their Influence on the Initiation and Course of the Disease.

Authors:  Maria Podbielska; Toshio Ariga; Anna Pokryszko-Dragan
Journal:  Int J Mol Sci       Date:  2022-05-10       Impact factor: 6.208

Review 4.  Recent advances in the mass spectrometric analysis of glycosphingolipidome - A review.

Authors:  Rodell C Barrientos; Qibin Zhang
Journal:  Anal Chim Acta       Date:  2020-05-24       Impact factor: 6.911

5.  Implications of Lymphocyte Anergy to Glycolipids in Multiple Sclerosis (MS): iNKT Cells May Mediate the MS Infectious Trigger.

Authors:  Edward L Hogan; Maria Podbielska; Joan O'Keeffe
Journal:  J Clin Cell Immunol       Date:  2013-06

6.  Myelin recovery in multiple sclerosis: the challenge of remyelination.

Authors:  Maria Podbielska; Naren L Banik; Ewa Kurowska; Edward L Hogan
Journal:  Brain Sci       Date:  2013-08-28

Review 7.  New Insights into Multiple Sclerosis Mechanisms: Lipids on the Track to Control Inflammation and Neurodegeneration.

Authors:  Maria Podbielska; Joan O'Keeffe; Anna Pokryszko-Dragan
Journal:  Int J Mol Sci       Date:  2021-07-07       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.